Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Fierce Pharma
ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma
The Tecvayli-Darzalex combo’s overall survival curve flattened, suggesting the potential of a cure.
Angus Liu
Dec 9, 2025 7:30am
Crescent inks $80M Kelun deal, adding ADC to mix with bispecific
Dec 4, 2025 9:50am
GSK pens $50M pact to join Big Pharma peers in emerging modality
Nov 19, 2025 4:40am
Pfizer lays out its PD-1xVEGF bispecific research strategy
Nov 11, 2025 11:43am
Lilly inks $345M antibody pact with XtalPi subsidiary
Nov 5, 2025 7:00am
Neok exits stealth with $75M to take bispecific ADCs into clinic
Nov 4, 2025 7:00am
